- Home
- FSLR vs BBIO Comparison
FSLR vs BBIO Comparison
Compare FSLR & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FSLR | BBIO |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.1B | 15.9B |
| IPO Year | 2006 | 2019 |
Fundamental Metrics
Financial Performance| Metric | FSLR | BBIO |
|---|---|---|
| Price | $178.83 | $64.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 36 | 22 |
| Target Price | ★ $275.44 | $109.05 |
| AVG Volume (30 Days) | 2.1M | ★ 2.8M |
| Earning Date | 10-29-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.22 | N/A |
| EPS | ★ 7.14 | N/A |
| Revenue | ★ $5,219,376,000.00 | $502,076,000.00 |
| Revenue This Year | N/A | $105.28 |
| Revenue Next Year | $18.03 | $64.62 |
| P/E Ratio | $26.00 | ★ N/A |
| Revenue Growth | 24.09 | ★ 126.26 |
| 52 Week Low | $168.60 | $52.75 |
| 52 Week High | $320.95 | $93.42 |
Technical Indicators
Market Signals| Indicator | FSLR | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 42.28 | 38.35 |
| Support Level | $168.60 | $63.22 |
| Resistance Level | $251.62 | $69.47 |
| Average True Range (ATR) | 5.70 | 1.98 |
| MACD | 1.50 | 0.24 |
| Stochastic Oscillator | 51.79 | 40.11 |
Price Performance
Historical ComparisonAbout FSLR First Solar Inc.
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and India.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.